SPPI News and Press, Spectrum Pharmaceuticals Inc. From 02/26/21

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on interim safety evaluation of same-day dosing of ROLONTIS ® (eflapegrastim) in patients with early-stage breast cance...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced two presentations, one oral and one eposter, at the upcoming European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Co...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day. The fireside chat is scheduled for Thursday,...

Nasdaq & NYSE Penny Stocks To Watch This Week We always talk about following trends when it comes to penny stocks . It might be a niche like electric vehicles or an entire sector like biotech. On this note, the latter has been one of the hottest corners of the stock market today...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of the ZENITH20 clinical trial. In addition...

Cullinan Management (CGEM) has priced upsized initial public offering of 11.9M common shares at $21/share, for expected gross proceeds of ~$249.9M.The company previously planned to raise $195M by offering 10M shares at a price range of $19 to $20 above the original offering of 8.3M shares at ...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will provide an overview of the company's business strategy and development-stage programs at three upcoming virtual investor conferen...

Gainers: [[MGNI]] +15.1%. [[SCPS]] +11.4%. [[OCN]] +10.5%. [[CLNE]] +6.9%. [[AMTX]] +4.7%.Losers: [[VYGR]] -11.9%. [[YCBD]] -11.4%. [[SPPI]] -9.4%. [[AHT]] -9.0%. [[ABCL]] -8.7%. For further details see: MGNI, SCPS, YCBD and SPPI among after-hours movers

Spectrum Pharmaceuticals (SPPI) falls -5.7% in the post-market after the company said the Cohort 3 failed to meet the primary endpoint in a pivotal Phase 2 trial for poziotinib in non-small cell lung cancer.However, the FDA has agreed to an NDA based on data from Cohort 2 ...

FDA agrees to the submission of an NDA for poziotinib for non-small cell lung cancer (NSCLC) in previously treated patients with HER2 exon 20 insertion mutations, NDA submission planned for 2021 Cohort 3 of the ZENITH20 clinical trial, which enrolled first-line NSCLC patients ...